[Editor's note: An earlier version of this article referenced Pfizer's Xeljanz in relation to psoriasis. However, Xeljanz only treats psoriatic arthritis. This has been corrected.]
Johnson & Johnson (JNJ) reported decent Q1 2018 results. The company grew revenue by 13% Y/Y; some of it was driven by the acquisition of Actelion - a leader in pulmonary hypertension. J&J expects to deliver organic revenue growth in the low single digits for 2018. That could be one reason why the stock sold off after earnings. The growth of Stelara (Crohn's disease, psoriasis) and the contribution from Tremfya (moderate-to-severe plaque psoriasis) were impressive.
Stelara's revenue of $1.1 billion was down 2% sequentially and up 54% Y/Y. Meanwhile, Tremfya generated $72 million in revenue, up 54% sequentially. The drug was launched in Q3 2017 and has generated about $120 million since inception. Stelera's sales only fell off slightly, despite the impressive start from Tremfya. I suspected Tremfya's success had to come at the expense of competing drugs like Novartis's (NVS) Cosentyx, Lilly's (LLY) Taltz or Celgene's (CELG) Otezla.


